$OGN
Organon & Co. Stock $ogn

$ogn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024006733 Filed on February 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.622B	$1.598B	$6.263B
YoY Change	5.46%	7.61%	1.44%
Cost Of Revenue	$665.0M	$666.0M	$2.468B
YoY Change	14.66%	12.12%	7.59%
Gross Profit	$957.0M	$932.0M	$3.795B
YoY Change	-0.1%	4.6%	-2.19%
Gross Profit Margin	59.0%	58.32%	60.59%
Selling, General & Admin	$431.0M	$422.0M	$1.715B
YoY Change	-0.92%	-10.21%	0.65%
% of Gross Profit	45.04%	45.28%	45.19%
Research & Development	$112.0M	$132.0M	$516.0M
YoY Change	-13.18%	-7.04%	9.55%
% of Gross Profit	11.7%	14.16%	13.6%
Depreciation & Amortization	$32.00M	$60.00M	$120.0M
YoY Change	14.29%	15.38%	25.0%
% of Gross Profit	3.34%	6.44%	3.16%
Operating Expenses	$543.0M	$554.0M	$2.229B
YoY Change	-3.72%	-9.48%	2.48%
Operating Profit	$414.0M	$378.0M	$1.566B
YoY Change	5.08%	35.48%	-8.15%
Interest Expense	$131.0M	-$146.0M	-$569.0M
YoY Change	-0.76%	-3.31%	-234.83%
% of Operating Profit	31.64%	-38.62%	-36.33%
Other Income/Expense, Net
YoY Change
Pretax Income	$236.0M	$104.0M	$673.0M
YoY Change	0.43%	-6.31%	-40.02%
Income Tax	$35.00M	-$442.0M	-$350.0M
% Of Pretax Income	14.83%	-425.0%	-52.01%
Net Earnings	$201.0M	$546.0M	$1.023B
YoY Change	13.56%	405.56%	11.56%
Net Earnings / Revenue	12.39%	34.17%	16.33%
Basic Earnings Per Share	$0.78		$4.01
Diluted Earnings Per Share	$0.78	$2.13	$3.99
COMMON SHARES
Basic Shares Outstanding	255.6M shares	255.6M shares	255.2M shares
Diluted Shares Outstanding	258.4M shares		256.3M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$575.0M	$693.0M	$693.0M
YoY Change	25.27%	-1.84%	-1.84%
Cash & Equivalents	$575.0M	$693.0M	$693.0M
Short-Term Investments
Other Short-Term Assets	$811.0M	$756.0M	$643.0M
YoY Change	7.42%	1.2%	0.94%
Inventory	$1.263B	$1.315B	$1.315B
Prepaid Expenses
Receivables	$1.547B	$1.744B	$1.744B
Other Receivables	$0.00	$0.00	$113.0M
Total Short-Term Assets	$4.196B	$4.508B	$4.508B
YoY Change	11.01%	14.68%	14.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.180B	$1.183B	$1.356B
YoY Change	11.85%	16.21%	9.98%
Goodwill	$4.603B	$4.603B
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.194B	$1.058B	$1.058B
YoY Change	69.6%	96.29%	96.29%
Total Long-Term Assets	$7.695B	$7.550B	$7.550B
YoY Change	10.2%	7.49%	7.49%
TOTAL ASSETS
Total Short-Term Assets	$4.196B	$4.508B	$4.508B
Total Long-Term Assets	$7.695B	$7.550B	$7.550B
Total Assets	$11.89B	$12.06B	$12.06B
YoY Change	10.48%	10.07%	10.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$955.0M	$1.314B	$1.314B
YoY Change	-4.12%	16.08%	16.08%
Accrued Expenses	$1.385B	$1.389B	$1.389B
YoY Change	20.43%	16.92%	16.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.000M	$9.000M	$9.000M
YoY Change	12.5%	12.5%	12.5%
Total Short-Term Liabilities	$2.545B	$2.918B	$2.918B
YoY Change	8.48%	16.16%	16.16%
LONG-TERM LIABILITIES
Long-Term Debt	$8.705B	$8.751B	$8.751B
YoY Change	0.02%	-1.73%	-1.73%
Other Long-Term Liabilities	$549.0M	$412.0M	$412.0M
YoY Change	30.4%	0.24%	0.24%
Total Long-Term Liabilities	$9.254B	$9.163B	$9.163B
YoY Change	1.42%	-1.64%	-1.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.545B	$2.918B	$2.918B
Total Long-Term Liabilities	$9.254B	$9.163B	$9.163B
Total Liabilities	$11.84B	$12.13B	$12.13B
YoY Change	3.25%	2.54%	2.37%
SHAREHOLDERS EQUITY
Retained Earnings	$573.0M	$443.0M
YoY Change	-378.16%	-233.84%
Common Stock	$52.00M	$28.00M
YoY Change	1633.33%	833.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.00M	-$70.00M	-$70.00M
YoY Change
Total Liabilities & Shareholders Equity	$11.89B	$12.06B	$12.06B
YoY Change	10.48%	10.07%	10.07%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$201.0M	$546.0M	$1.023B
YoY Change	13.56%	405.56%	11.56%
Depreciation, Depletion And Amortization	$32.00M	$60.00M	$120.0M
YoY Change	14.29%	15.38%	25.0%
Cash From Operating Activities	$76.00M	$397.0M	$799.0M
YoY Change	-33.33%	48.69%	-6.88%
INVESTING ACTIVITIES
Capital Expenditures	$46.00M	$79.00M	$251.0M
YoY Change	0.0%	21.54%	28.06%
Acquisitions
YoY Change
Other Investing Activities	-$50.00M	-$2.000M	-$1.000M
YoY Change		-150.0%	-99.15%
Cash From Investing Activities	-$96.00M	-$81.00M	-$260.0M
YoY Change	77.78%	32.79%	-38.1%
FINANCING ACTIVITIES
Cash Dividend Paid	$70.00M		$294.0M
YoY Change	-4.11%		1.38%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$2.000M		$338.0M
YoY Change	-99.21%		212.96%
Cash From Financing Activities	-$74.00M	-77.00M	-569.0M
YoY Change	-77.3%	-6.1%	31.41%
NET CHANGE
Cash From Operating Activities	$76.00M	397.0M	799.0M
Cash From Investing Activities	-$96.00M	-81.00M	-260.0M
Cash From Financing Activities	-$74.00M	-77.00M	-569.0M
Net Change In Cash	-$118.0M	239.0M	-$13.00M
YoY Change	-52.23%	92.74%	-58.06%
FREE CASH FLOW
Cash From Operating Activities	$76.00M	$397.0M	$799.0M
Capital Expenditures	$46.00M	$79.00M	$251.0M
Free Cash Flow	$30.00M	$318.0M	$548.0M
YoY Change	-55.88%	57.43%	-17.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Expense InterestExpense	527000000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42000000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11000000	usd
CY2023	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-15000000	usd
CY2022	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-15000000	usd
CY2021	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-17000000	usd
CY2023	ogn	Costs Expenses And Other CostsExpensesAndOther	5590000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	163000000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	220000000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	138000000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	43000000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.61
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001821825
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2021	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2023	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2022	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2021	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#DeferredIncomeTaxesAndOtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#DeferredIncomeTaxesAndOtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.organon.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.organon.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40235
CY2023	dei	Entity Registrant Name EntityRegistrantName	Organon & Co.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4838035
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Hudson Street, Floor 33
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Jersey City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07302
CY2023	dei	City Area Code CityAreaCode	(551)
CY2023	dei	Local Phone Number LocalPhoneNumber	430-6900
CY2023	dei	Security12b Title Security12bTitle	Common Stock ($0.01 par value)
CY2023	dei	Trading Symbol TradingSymbol	OGN
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5300000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	255638256	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.99
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Florham Park, New Jersey
CY2023	us-gaap	Revenues Revenues	6263000000	usd
CY2022	us-gaap	Revenues Revenues	6174000000	usd
CY2021	us-gaap	Revenues Revenues	6304000000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2515000000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2294000000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2382000000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1704000000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1668000000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	339000000	usd
CY2022	ogn	Costs Expenses And Other CostsExpensesAndOther	5052000000	usd
CY2021	ogn	Costs Expenses And Other CostsExpensesAndOther	4775000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	673000000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-350000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	205000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1023000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	917000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1351000000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	917000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1351000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.01
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.61
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.33
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.01
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.59
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.31
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.99
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.59
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.31
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	255239000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	254082000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253538000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	256270000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	255169000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254193000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1023000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	917000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1351000000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	25000000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-23000000	usd
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-8000000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	48000000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-74000000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	90000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-51000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	98000000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1046000000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	866000000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1449000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	693000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	706000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1744000000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1475000000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	110000000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	148000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1315000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1003000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	747000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4508000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3931000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1183000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1018000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4603000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	4603000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	533000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	649000000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	1231000000	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	754000000	usd
CY2023Q4	us-gaap	Assets Assets	12058000000	usd
CY2022Q4	us-gaap	Assets Assets	10955000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1314000000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1132000000	usd
CY2023Q4	ogn	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	1389000000	usd
CY2022Q4	ogn	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	1188000000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	206000000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	184000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2918000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2512000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8751000000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8905000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	47000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	19000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	412000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	411000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12128000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11847000000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255626000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255626000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	254370000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	254370000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	25000000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	443000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-331000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-541000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-564000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-892000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12058000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10955000000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5486000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1351000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	98000000	usd
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.56
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	145000000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38000000	usd
CY2021	ogn	Net Transfers In Connection With Separation NetTransfersInConnectionWithSeparation	664000000	usd
CY2021	ogn	Consideration Paid In Connection With The Separation ConsiderationPaidInConnectionWithTheSeparation	9000000000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1508000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	917000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-51000000	usd
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.12
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	290000000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64000000	usd
CY2022	ogn	Net Transfers In Connection With Separation NetTransfersInConnectionWithSeparation	-24000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-892000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1023000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23000000	usd
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.12
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	295000000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	84000000	usd
CY2023	ogn	Net Transfers In Connection With Separation NetTransfersInConnectionWithSeparation	-13000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-70000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1023000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	917000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1351000000	usd
CY2023	us-gaap	Depreciation Depreciation	120000000	usd
CY2022	us-gaap	Depreciation Depreciation	96000000	usd
CY2021	us-gaap	Depreciation Depreciation	92000000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	116000000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	116000000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	103000000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	9000000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7000000	usd
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired	8000000	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired	107000000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-485000000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	59000000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	18000000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-18000000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-31000000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26000000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-12000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	212000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	123000000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	277000000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	230000000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	10000000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-353000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-237000000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	663000000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	102000000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	172000000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	329000000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-164000000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	16000000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	7000000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-119000000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-16000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	8000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-55000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	799000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	858000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2160000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251000000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	196000000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192000000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000000	usd
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	8000000	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	107000000	usd
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	104000000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	124000000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	192000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-260000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-420000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-481000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	80000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9470000000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	338000000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	108000000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	112000000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	118000000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1512000000	usd
CY2023	ogn	Consideration Paid In Connection With Separation ConsiderationPaidInConnectionWithSeparation	0	usd
CY2022	ogn	Consideration Paid In Connection With Separation ConsiderationPaidInConnectionWithSeparation	0	usd
CY2021	ogn	Consideration Paid In Connection With Separation ConsiderationPaidInConnectionWithSeparation	9000000000	usd
CY2023	ogn	Net Financing Transfers NetFinancingTransfers	0	usd
CY2022	ogn	Net Financing Transfers NetFinancingTransfers	24000000	usd
CY2021	ogn	Net Financing Transfers NetFinancingTransfers	-440000000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	17000000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11000000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	294000000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	290000000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	145000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-569000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-433000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-977000000	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	298000000	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-356000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-58000000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17000000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-36000000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23000000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13000000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31000000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	667000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	706000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	737000000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12000000	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	58000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	693000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	706000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	737000000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	693000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	706000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	737000000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Background and Nature of Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon & Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations include the following product portfolios:</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Women's Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon's women's health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant) (sold as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon NXT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ in some countries outside the United States) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Follistim AQ®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (follitropin beta injection) (marketed in most countries outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puregon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women's health products include the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted and a license from Daré Biosciences for the global commercial rights to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xaciato</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">® (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis ("BV") in females 12 years of age and older. In October 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xaciato </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was launched in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon's current portfolio spans across immunology and oncology treatments. Organon's oncology biosimilars; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ontruzant®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trastuzumab-dttb) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aybintio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bevacizumab), have been launched in more than 20 countries and Organon's immunology biosimilars; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brenzys</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etarnarcept), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renflexi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab-abda) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab-bwwd), have been launched in five countries. All five biosimilars in Organon's portfolio have launched in Canada, and three biosimilars;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ontruzant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renflexis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been launched in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Established Brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time.</span></div>
CY2023Q4	ogn	Number Of Medicines And Products NumberOfMedicinesAndProducts	60	medicineandproduct
CY2023Q4	ogn	Number Of Manufacturing Facilities NumberOfManufacturingFacilities	6	manufacturingfacility
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Organon and Merck & Co. ("Merck") entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation"). On June 2, 2021, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on June 2, 2021, the Company's historical combined financial statements were prepared on a standalone basis and were derived from Merck's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are now referred to as "Consolidated Financial Statements," and have been prepared pursuant to the rules and regulations for reporting on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical results prior to Separation included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck ("Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Consolidated Financial Statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods Prior to Separation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets, liabilities, revenue and expenses of the Company were reflected in the Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applied by Merck. The Consolidated Financial Statements did not purport to reflect what the Company's results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements were prepared following a legal entity approach, which resulted in the inclusion of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain assets and liabilities, results of operations and cash flows attributable to the sales of Organon Products that were contributed to Organon prior to the consummation of the Separation.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Transferred Entities, which have historically included the results from the sales of both Organon Products and the Merck Retained Products. Each Transferred Entity's historical operations, including its results of operations, assets and liabilities, and cash flows have been fully reflected in the Consolidated Financial Statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In contemplation of the Separation, the Merck Retained Products business of the Transferred Entities was distributed to Merck and its affiliates ("MRP Distribution") and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's businesses had historically functioned together with the other businesses controlled by Merck. Accordingly, the Company relied on Merck's corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">expenses related to Merck support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">certain manufacturing and supply costs incurred by Merck's manufacturing division, including facility management, distribution, logistics, planning and global quality. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">certain costs incurred by Merck's human health division in relation to selling and marketing activities, and related administrative support functions, that are not routinely allocated to therapeutic areas.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">certain costs incurred by Merck's research laboratories for activities related to drug discovery and development, as well as medical and regulatory affairs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">restructuring costs (see Note 8 "Restructuring") and stock-based compensation expenses (see Note 7 "Stock-Based Compensation Plans"); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company's employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck maintained various employee benefit plans in which the Company's employees participated during periods prior to the Separation, a portion of the costs associated with these plans was included in the Company's Consolidated Financial Statements. Certain pension assets and obligations were transferred by Merck into legal entities established to operate the Organon Products business (the "Organon Entities") that are the plan sponsor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Company was routinely transferred into accounts managed by Merck's centralized treasury function and cash disbursements for the Company's operations prior to the Separation were funded as needed by Merck. Cash and cash equivalents of the Organon Entities and the Transferred Entities were reflected in the Company's Consolidated Balance Sheet. Balances held by the Organon Entities and the Transferred Entities with Merck for cash transfers and loans were reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due to related party</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to Separation. All other cash, cash equivalents, short-term investments and related transfers between Merck and the Company were generally held centrally through accounts controlled and maintained by Merck and were not specifically identifiable to the Company. Accordingly, such balances were accounted for through</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net investment from Merck & Co., Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Merck's third-party debt and related interest expense were not attributed to the Company because the Company was not the legal obligor of the debt and the borrowings were not specifically identifiable to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Organon Entities and the Transferred Entities, transactions with Merck affiliates that were included in the Consolidated Statement of Income and related balances were reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due to related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due from related party</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Consolidated Balance Sheet, as applicable. Other balances between the Company and Merck were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. See Note 19 "Third-Party Arrangements and Related Party Disclosures" for additional details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the separate legal entities that made up the Company's business were not historically held by a single legal entity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was shown in lieu of stockholders' equity in these Consolidated Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represented Merck's interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The Company's operations are included in the tax returns of certain Organon Entities, Transferred Entities or the respective Merck entities of which the Company's business was a part.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As of Separation Date</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Consolidated Balance Sheet prior to the Separation, have been retained by Merck post-Separation and therefore were transferred to Merck through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Company's Consolidated Financial Statements. As part of the Separation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Separation, additional pension assets and obligations were transferred to Organon through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and the Company recorded these in the Consolidated Balance Sheet. See Note 15 "Pension and Other Postretirement Benefit Plans" for details. Additionally, stock-based awards were converted in accordance with the employee matters agreement (the "Employee Matters Agreement") entered into between Organon and Merck in connection with the spinoff. See Note 7 "Stock-Based Compensation Plans" for details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods Post Separation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Separation, certain functions continue to be provided by Merck under the Transition Services Agreement or are being performed using the Company's own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck or its applicable affiliate, and Merck manufactures certain products for the Company or its applicable affiliate. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rate may differ from the amounts reported in the historical periods. As of June 2, 2021 and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and accounts within Organon have been eliminated.</span></div>
CY2023Q4	ogn	Accrual For Chargebacks AccrualForChargebacks	87000000	usd
CY2023Q4	ogn	Accrual For Rebates AccrualForRebates	417000000	usd
CY2022Q4	ogn	Accrual For Chargebacks AccrualForChargebacks	78000000	usd
CY2022Q4	ogn	Accrual For Rebates AccrualForRebates	307000000	usd
CY2023	ogn	Revenue Recognition Goods Goods Return Period After To Expiration Date RevenueRecognitionGoodsGoodsReturnPeriodAfterToExpirationDate	P12M
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.99
CY2023Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	113000000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	110000000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	18000000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	9000000	usd
CY2023	us-gaap	Depreciation Depreciation	120000000	usd
CY2022	us-gaap	Depreciation Depreciation	96000000	usd
CY2021	us-gaap	Depreciation Depreciation	92000000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	209000000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	255000000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	236000000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.59
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.31
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	35000000	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Revenues Revenues	6263000000	usd
CY2022	us-gaap	Revenues Revenues	6174000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	The presentation of these Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported. Estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, amounts recorded for contingencies, environmental liabilities, pension and other postretirement benefit plan assumptions, stock-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill), investments, and taxes on income. Additionally, estimates are used in acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&D, intangible assets and contingent consideration), as well as subsequent fair value measurements. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to Separation, estimates were used in determining the allocation of costs and expenses from Merck, and were used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, valuation of goodwill and intangibles, amounts recorded for contingencies, environmental liabilities and other reserves, pension and stock-based compensation assumptions, restructuring costs, and taxes on income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div>
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1023000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	917000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1351000000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1023000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	917000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1351000000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	255239000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	254082000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253538000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1031000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1087000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	655000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	256270000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	255169000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254193000	shares
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.01
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.61
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.33
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.61
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.99
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.59
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.31
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2023	us-gaap	Revenues Revenues	6263000000	usd
CY2022	us-gaap	Revenues Revenues	6174000000	usd
CY2021	us-gaap	Revenues Revenues	6304000000	usd
CY2021	ogn	Incremental Share Based Payment Arrangement Expense IncrementalShareBasedPaymentArrangementExpense	17000000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	101000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	59000000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	21000000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	16000000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	12000000	usd
CY2021Q2	ogn	Share Based Compensation Arrangement By Share Based Payment Award Options Converted In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConvertedInPeriod	4100000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0482
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0312
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0322
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0356
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0247
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0092
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4230
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4343
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4580
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M20D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M20D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M20D
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	321000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4729000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.34
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	9.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1124000000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.52
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.55
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	95000000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	36.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	9.71
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5758000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.20
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.51
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5623000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.20
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3311000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	33.79
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M9D
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	153000000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M9D
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-91000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.136
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-113000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.101
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-39000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.025
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-13000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	-0.019
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-2000000	usd
CY2023	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	130	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.03
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	20000000	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	62000000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	28000000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	21000000	usd
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	8000000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	61000000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	20000000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	141000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	236000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	-0.001
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-32000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	-0.021
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	-686000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-1.020
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	0
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	-75000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.049
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.008
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.002
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	54000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.080
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	57000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.051
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	17000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.011
CY2023	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Amount EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementAmount	46000000	usd
CY2023	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Percent EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementPercent	0.068
CY2022	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Amount EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementAmount	13000000	usd
CY2022	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Percent EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementPercent	0.012
CY2021	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Amount EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementAmount	0	usd
CY2021	ogn	Effective Income Tax Rate Reconciliation Interest Expense Disallowance Tax Settlement Percent EffectiveIncomeTaxRateReconciliationInterestExpenseDisallowanceTaxSettlementPercent	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	208000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.309
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.004
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.003
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	12000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.010
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-7000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-350000000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.522
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	205000000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.183
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	178000000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.117
CY2021Q4	us-gaap	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Liability TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability	0	usd
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	4000000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.522
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.183
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.117
CY2021	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	75000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	927000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	164000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-554000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-451000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-96000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1227000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1573000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1625000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	673000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1122000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1529000000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	47000000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	51000000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	41000000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	87000000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	172000000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	435000000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-10000000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	135000000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	223000000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	466000000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-52000000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-38000000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-64000000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-428000000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	22000000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-220000000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5000000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2000000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4000000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-485000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18000000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-288000000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-350000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	205000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	178000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	3000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	10000000	usd
CY2023Q4	ogn	Deferred Tax Asset Tax Deferred Expense Reserve And Accrual Reserves And Allowances DeferredTaxAssetTaxDeferredExpenseReserveAndAccrualReservesAndAllowances	38000000	usd
CY2022Q4	ogn	Deferred Tax Asset Tax Deferred Expense Reserve And Accrual Reserves And Allowances DeferredTaxAssetTaxDeferredExpenseReserveAndAccrualReservesAndAllowances	51000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	22000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	18000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	11000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	5000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	3000000	usd
CY2023Q4	ogn	Deferred Tax Assets Operating Leases Right Of Use Asset DeferredTaxAssetsOperatingLeasesRightOfUseAsset	38000000	usd
CY2022Q4	ogn	Deferred Tax Assets Operating Leases Right Of Use Asset DeferredTaxAssetsOperatingLeasesRightOfUseAsset	44000000	usd
CY2023Q4	ogn	Deferred Tax Liabilities Operating Lease Liability DeferredTaxLiabilitiesOperatingLeaseLiability	38000000	usd
CY2022Q4	ogn	Deferred Tax Liabilities Operating Lease Liability DeferredTaxLiabilitiesOperatingLeaseLiability	44000000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	72000000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	37000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	17000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	26000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	41000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	59000000	usd
CY2023Q4	ogn	Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards	35000000	usd
CY2022Q4	ogn	Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards	65000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	37000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1172000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	102000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	427000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	127000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	309000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	863000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	102000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	375000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	127000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	761000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	248000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35000000	usd
CY2023	ogn	Valuation Allowance Deferred Tax Asset Additions Charged To Expense ValuationAllowanceDeferredTaxAssetAdditionsChargedToExpense	257000000	usd
CY2022	ogn	Valuation Allowance Deferred Tax Asset Additions Charged To Expense ValuationAllowanceDeferredTaxAssetAdditionsChargedToExpense	17000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	309000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	65000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	309000000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	309000000	usd
CY2023	ogn	Valuation Allowance Deferred Tax Asset Additions Charged To Expense ValuationAllowanceDeferredTaxAssetAdditionsChargedToExpense	257000000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17000000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	135000000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	214000000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	131000000	usd
CY2023Q4	ogn	Deferred Tax Liabilities Intra Entity Transfers Of Inventory DeferredTaxLiabilitiesIntraEntityTransfersOfInventory	396000000	usd
CY2022Q4	ogn	Deferred Tax Liabilities Intra Entity Transfers Of Inventory DeferredTaxLiabilitiesIntraEntityTransfersOfInventory	368000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	93000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78000000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	219000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	32000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	30000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	23000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	7000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	18000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	49000000	usd
CY2023	ogn	Unrecognized Tax Benefits Decrease Resulting From Spinoff Transaction UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction	0	usd
CY2022	ogn	Unrecognized Tax Benefits Decrease Resulting From Spinoff Transaction UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction	0	usd
CY2021	ogn	Unrecognized Tax Benefits Decrease Resulting From Spinoff Transaction UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction	108000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	7000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	12000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	15000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	10000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	115000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	93000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78000000	usd
CY2021	ogn	Unrecognized Tax Benefits Decrease Resulting From Spinoff Transaction UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction	108000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	115000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	115000000	usd
CY2022Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	27000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	40000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	35000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	566000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	482000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	110000000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	44000000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	684000000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	601000000	usd
CY2023Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	65000000	usd
CY2022Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	44000000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	1425000000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1171000000	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	0	usd
CY2022Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	20000000	usd
CY2023Q4	ogn	Inventory Net And Inventory Noncurrent InventoryNetAndInventoryNoncurrent	1425000000	usd
CY2022Q4	ogn	Inventory Net And Inventory Noncurrent InventoryNetAndInventoryNoncurrent	1151000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1315000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1003000000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	110000000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	148000000	usd
CY2023Q4	us-gaap	Lifo Inventory Amount LIFOInventoryAmount	105000000	usd
CY2022Q4	us-gaap	Lifo Inventory Amount LIFOInventoryAmount	77000000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	1000000000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	318000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	114000000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	117000000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1017000000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	902000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1183000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1018000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24521000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23988000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	533000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24516000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23867000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	649000000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9000000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7000000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	112000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	111000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	105000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	48000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	40000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	117000000	usd
CY2023	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	10000000	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-10000000	usd
CY2021	ogn	Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Foreign currency (loss) gain in Other comprehensive income
CY2023	ogn	Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Foreign currency (loss) gain in Other comprehensive income
CY2022	ogn	Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Foreign currency (loss) gain in Other comprehensive income
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-56000000	usd
CY2023Q4	us-gaap	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized	66000000	usd
CY2022Q4	us-gaap	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized	43000000	usd
CY2021	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	29000000	usd
CY2021Q2	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	50000000	usd
CY2023	ogn	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Plan Amendment Estimated Average Service Period DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPlanAmendmentEstimatedAverageServicePeriod	P8Y
CY2023	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	34000000	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	17000000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	22000000	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	17000000	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	5000000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2000000	usd
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2000000	usd
CY2023	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	6000000	usd
CY2022	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	4000000	usd
CY2021	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	3000000	usd
CY2023	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	1000000	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	usd
CY2021	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-2000000	usd
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	15000000	usd
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	20000000	usd
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	18000000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	16000000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	14000000	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	9000000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-4000000	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	5000000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	7000000	usd
CY2023	us-gaap	Defined Benefit Plan Other Costs DefinedBenefitPlanOtherCosts	2000000	usd
CY2022	us-gaap	Defined Benefit Plan Other Costs DefinedBenefitPlanOtherCosts	3000000	usd
CY2023	ogn	Defined Benefit Plan Plan Assets Net Transfer Of Plan Assets From Merck Affiliates DefinedBenefitPlanPlanAssetsNetTransferOfPlanAssetsFromMerckAffiliates	3000000	usd
CY2022	ogn	Defined Benefit Plan Plan Assets Net Transfer Of Plan Assets From Merck Affiliates DefinedBenefitPlanPlanAssetsNetTransferOfPlanAssetsFromMerckAffiliates	1000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	149000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	114000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	161000000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	189000000	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	17000000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	22000000	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	5000000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2000000	usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	31000000	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-41000000	usd
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	5000000	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	7000000	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	12000000	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-7000000	usd
CY2023	us-gaap	Defined Benefit Plan Other Changes DefinedBenefitPlanOtherChanges	2000000	usd
CY2022	us-gaap	Defined Benefit Plan Other Changes DefinedBenefitPlanOtherChanges	1000000	usd
CY2023	ogn	Defined Benefit Plan Benefit Obligation Net Transfer Of Benefit Obligations From Merck Affiliates DefinedBenefitPlanBenefitObligationNetTransferOfBenefitObligationsFromMerckAffiliates	3000000	usd
CY2022	ogn	Defined Benefit Plan Benefit Obligation Net Transfer Of Benefit Obligations From Merck Affiliates DefinedBenefitPlanBenefitObligationNetTransferOfBenefitObligationsFromMerckAffiliates	2000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	226000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	161000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-77000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-47000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	0	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1000000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	1000000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	1000000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	76000000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	47000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	218000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	150000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Pension Plan With Projected Benefit Obligation In Excess Of Plan Assets Plan Assets DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets	141000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plan With Projected Benefit Obligation In Excess Of Plan Assets Plan Assets DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets	103000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	171000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	113000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	107000000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	73000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	15000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	9000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	8000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	9000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	10000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	11000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	70000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-28000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	28000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	4000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	1000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-2000000	usd
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0382
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0149
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0148
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0444
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0405
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0450
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0298
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0275
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0318
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0277
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0382
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0149
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0283
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0298
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0275
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	39000000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	23000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	84000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	105000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	8760000000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	8913000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8751000000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8905000000	usd
CY2021Q2	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	9000000000	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	8253000000	usd
CY2022Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	8294000000	usd
CY2023	ogn	Debt Instrument Interest Payments DebtInstrumentInterestPayments	495000000	usd
CY2023	ogn	Debt Instrument Average Maturity DebtInstrumentAverageMaturity	P5Y
CY2023	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.057
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	6803000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2003000000	usd
CY2023	us-gaap	Lease Cost LeaseCost	67000000	usd
CY2022	us-gaap	Lease Cost LeaseCost	61000000	usd
CY2021	us-gaap	Lease Cost LeaseCost	66000000	usd
CY2023	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	56000000	usd
CY2022	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	55000000	usd
CY2021	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	41000000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25000000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28000000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	241000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	173000000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	215000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	171000000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	199000000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.048
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	52000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	48000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	29000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	33000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	189000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	171000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	111000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	13000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	98000000	usd
CY2021	ogn	Transfers Of Benefit Plans To Related Party Affiliates TransfersOfBenefitPlansToRelatedPartyAffiliates	11000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-46000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	5000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-51000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	19000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-4000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	23000000	usd
CY2021Q2	ogn	Transition Services Agreement Terms Services Termination Period TransitionServicesAgreementTermsServicesTerminationPeriod	P25M
CY2022	ogn	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	168000000	usd
CY2022	ogn	Related Party Cost Allocations Excluding Non Cash Share Based Compensation RelatedPartyCostAllocationsExcludingNonCashShareBasedCompensation	209000000	usd
CY2022	ogn	Related Party Tax Payments RelatedPartyTaxPayments	259000000	usd
CY2022	ogn	Related Party Allocated Derivative Gain Loss On Derivative RelatedPartyAllocatedDerivativeGainLossOnDerivative	-88000000	usd
CY2021	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Continuing Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInContinuingOperations	-388000000	usd
CY2022	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Discontinued Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInDiscontinuedOperations	597000000	usd
CY2021	ogn	Related Party Net Transfers Included Net Cash Provided By Used In Cash Flows RelatedPartyNetTransfersIncludedNetCashProvidedByUsedInCashFlows	209000000	usd
CY2022	ogn	Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense	32000000	usd
CY2022	ogn	Related Party Transaction Contributions Distributions To Affiliates RelatedPartyTransactionContributionsDistributionsToAffiliates	778000000	usd
CY2022	ogn	Related Party Derecognition Of Employee Benefit Plan Transfers Recognized In Accumulated Other Comprehensive Income RelatedPartyDerecognitionOfEmployeeBenefitPlanTransfersRecognizedInAccumulatedOtherComprehensiveIncome	13000000	usd
CY2021	ogn	Net Transfer NetTransfer	-588000000	usd
CY2022	ogn	Separation Agreement Provisional Information Initial Accounting Incomplete Adjustment Net Transfers Included In Net Cash Provided By Used In Continuing Operations SeparationAgreementProvisionalInformationInitialAccountingIncompleteAdjustmentNetTransfersIncludedInNetCashProvidedByUsedInContinuingOperations	52000000	usd
CY2023Q4	us-gaap	Litigation Reserve LitigationReserve	20000000	usd
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	17000000	usd
CY2023	ogn	Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag	environmental matters
CY2022	ogn	Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag	environmental matters
CY2023Q4	us-gaap	Accrual For Environmental Loss Contingencies AccrualForEnvironmentalLossContingencies	19000000	usd
CY2022Q4	us-gaap	Accrual For Environmental Loss Contingencies AccrualForEnvironmentalLossContingencies	20000000	usd
CY2023	ogn	Term For Paying Off Environmental Liabilities TermForPayingOffEnvironmentalLiabilities	P15Y
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-006733-index-headers.html	Edgar Link	pending
0001628280-24-006733-index.html	Edgar Link	pending
0001628280-24-006733.txt	Edgar Link	pending
0001628280-24-006733-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ogn-12312023xexhibit1021.htm	Edgar Link	pending
ogn-12312023xexhibit231.htm	Edgar Link	pending
ogn-20231231.htm	Edgar Link	pending
ogn-20231231.xsd	Edgar Link	pending
ogn-20231231_g1.gif	Edgar Link	pending
ogn-20231231_g10.gif	Edgar Link	pending
ogn-20231231_g11.gif	Edgar Link	pending
ogn-20231231_g12.gif	Edgar Link	pending
ogn-20231231_g13.jpg	Edgar Link	pending
ogn-20231231_g14.gif	Edgar Link	pending
ogn-20231231_g15.gif	Edgar Link	pending
ogn-20231231_g16.jpg	Edgar Link	pending
ogn-20231231_g17.jpg	Edgar Link	pending
ogn-20231231_g2.gif	Edgar Link	pending
ogn-20231231_g3.gif	Edgar Link	pending
ogn-20231231_g4.gif	Edgar Link	pending
ogn-20231231_g5.gif	Edgar Link	pending
ogn-20231231_g6.gif	Edgar Link	pending
ogn-20231231_g7.gif	Edgar Link	pending
ogn-20231231_g8.gif	Edgar Link	pending
ogn-20231231_g9.gif	Edgar Link	pending
ogn12312023-exhibit1038.htm	Edgar Link	pending
ogn12312023-exhibit211.htm	Edgar Link	pending
ogn12312023-exhibit311.htm	Edgar Link	pending
ogn12312023-exhibit312.htm	Edgar Link	pending
ogn12312023-exhibit321.htm	Edgar Link	pending
ogn12312023-exhibit322.htm	Edgar Link	pending
ogn12312023-exhibit971.htm	Edgar Link	pending
ogn-20231231_lab.xml	Edgar Link	unprocessable
ogn-20231231_pre.xml	Edgar Link	unprocessable
ogn-20231231_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ogn-20231231_cal.xml	Edgar Link	unprocessable
ogn-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGN
Organon & Co. Stock $ogn

2024 Q1 Form 10-K Financial Statement

#000162828024006733 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGN Organon & Co. Stock $ogn

2024 Q1 Form 10-K Financial Statement

#000162828024006733 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGN
Organon & Co. Stock $ogn